Hygroton (Chlortalidone)

Chlortalidone works by blocking the sodium‑chloride cotransporter in the distal convoluted tubule of the kidney. This inhibition reduces reabsorption of sodium and chloride, leading to increased urinary loss of these ions together with water. The resulting decrease in extracellular fluid volume lowers blood pressure, while modest arterial dilation adds to its antihypertensive effect.

The appropriate dose of chlortalidone is individualized by the prescribing clinician based on the patient’s medical condition, response to therapy, and laboratory values. Dosage decisions consider factors such as severity of hypertension or edema, renal function, and concurrent medications. Patients should follow the exact regimen provided by their healthcare professional.

Chlortalidone is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Limited data are available for lactating women; therefore, a healthcare provider should evaluate the risk‑benefit ratio before use while breastfeeding.

To place an order, submit an enquiry on the Hygroton product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements if applicable) and assist with import documentation.

Compared with thiazide diuretics such as hydrochlorothiazide, chlortalidone has a longer half‑life, providing more sustained blood pressure control and fluid removal. It is often preferred for patients who need once‑daily dosing or who have resistant hypertension. However, like other diuretics, it shares similar electrolyte‑related risks, so monitoring is essential regardless of the specific agent chosen.

Hygroton tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging is tightly closed. Do not store in the bathroom or near heat sources, and keep out of reach of children.

Hygroton is taken orally, usually with a full glass of water. It can be taken with or without food, but consistent timing each day helps maintain stable blood levels. Patients should swallow the tablet whole and avoid crushing or chewing unless specifically instructed by a healthcare professional.

The most serious risks include severe electrolyte disturbances such as hypokalemia or hyponatremia, which can cause cardiac arrhythmias, muscle weakness, or seizures. Acute gout attacks may occur due to increased uric acid levels. Rarely, allergic reactions like rash, angioedema, or anaphylaxis can develop. Patients should seek immediate medical attention if they experience symptoms such as irregular heartbeat, severe muscle cramps, sudden joint pain, or signs of an allergic reaction.

Hygroton should be avoided in patients with known hypersensitivity to chlortalidone or other sulfonamide‑derived drugs. It is contraindicated in individuals with anuria (absence of urine output) or severe renal impairment. Caution is also advised for patients with gout, uncontrolled diabetes, or those taking medications that may interact significantly, such as lithium or certain NSAIDs. A healthcare professional must evaluate suitability before initiating therapy.